“A COMBINED ATMP STRATEGY TO SUPPLEMENT CRITICAL SIZED BONE FRACTURE HEALING”
Grant Agreement: 874889
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874889
The overarching aim of this project is to develop a modular graft system for bone healing and regeneration in cases of major orthopaedic fracture and bone loss, particularly those resulting from trauma. Non-union fractures are common and their treatment is a significant healthcare burden when considering the growing incidence of osteoporosis related fragility fractures. Over 2 million surgical cases require bone graft each year worldwide, however, current products and clinical practice have their limitations. We aim to develop graft technologies which provide the efficacy of autograft with the benefits of being an off-the-shelf surgical product.HEALIKICK consortium will implement a surgical co-administration of two robust technologies 1) a granular graft material with a highly osteogenic coating that presents relevant biologics very efficiently and 2) pre-differentiated osteogenic adipose mesenchymal stromal cells (MSCs) that together will underpin efficient bone regeneration.
Histocell will contribute to HEALIKICK with its expertise on biomaterial development, the design of regenerative therapies and its expertise on GMP cell manufacturing for cell therapies. Within the project we aim to take the two technologies into GMP and ISO rated manufacture as required for any clinical therapy. Consortium partners will then implement these therapies in pre-clinical studies to obtain efficacy and safety data to support a full clinical trial application.